To date, the DCB has acquired four new technologies with medical applications, including a platform to generate human monoclonal antibodies against entrovirus type 71, and drugs with the potential to treat complications resulting from chronic heart failure and diabetes. The center is also beginning to get its hands on very promising technologies used to modify genes and proteins.
目前 BioFronts 已掌握了四種新藥的製程技術，包括腸病毒七十一型抗體藥物，及針對慢性心臟衰竭及糖尿病併發症藥物等，對於「基因修飾」、「蛋白質修飾」等生技領域的前瞻技術也有初步的掌握，前景相當看好。